Canine lymphoma represents the most common and deadly cancer afflicting dogs in the United States. According to CSU Animal Cancer Center, lymphoma represents nearly 20% of its total cancer cases. While traditional chemotherapy has been shown to be an effective therapeutic approach for treating lymphoma in companion animals, nearly all treated animals will ultimately relapse, leaving them with very few viable medical options.
VDC-1101 is a novel cancer pro-drug, discovered by Gilead Sciences, Inc., (GS 9219) designed specifically to target and attack cancer cells implicated in lymphoma. An extensive body of safety and efficacy data has already been generated in canines afflicted with lymphoma, and VDC-1101 is poised to enter a pivotal registration study in the next 12-18 months.
VDC-1101 was acquired in 2011, see press release.